Base de dados : LILACS
Pesquisa : C04.557.470.200.025.255 [Categoria DeCS]
Referências encontradas : 445 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 45 ir para página                         

  1 / 445 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1135640
Autor: Vielmo, Andréia; Panziera, Welden; Bianchi, Matheus V; Argenta, Fernando F; Lorenzo, Cíntia De; Vielmo, Luís A; Pavarini, Saulo P; Driemeier, David.
Título: Primary hepatic neoplasms in cattle / Neoplasmas hepáticos primários de bovinos
Fonte: Pesqui. vet. bras = Braz. j. vet. res;40(6):409-416, June 2020. tab, ilus.
Idioma: en.
Resumo: Primary hepatic neoplasms are mostly detected in cattle as incidental findings in slaughterhouses or diagnosed at the necropsy, wherein it may be related to the cause of death. A proper characterization of primary hepatic neoplasms is essential to provide an accurate diagnosis, especially at the slaughter lines, in order to reduce erroneous condemnations. This work aimed to characterize the gross, histological, and immunohistochemical features of primary liver neoplasms detected in slaughtered cattle in Southern Brazil. Nineteen primary hepatic neoplasms were identified. Grossly, these lesions were classified according to their distribution, as focal, multifocal, or diffuse. Histologically, the shape and arrangement of the cells, as well as possible malignant features were evaluated. Immunohistochemistry (IHC) was also performed for biliary epithelium (anti-CK7) and hepatocytes (anti-Hep Par-1) markers. Hepatocellular carcinoma (84.2%) was the most frequently detected hepatic neoplasm, followed by cholangiocarcinoma (15.8%), and these were only identified in adult cows. Hepatocellular carcinomas occurred as solitary masses or multifocal nodules, which on the cut surface were often green. Cholangiocarcinomas occurred as multifocal nodules, occasionally showing an umbilicated appearance. Histologically, hepatocellular carcinomas had mostly trabecular and solid patterns, while cholangiocarcinomas presented mostly a solid arrangement. Upon IHC, all hepatocellular carcinomas were immunolabeled for anti-Hep Par-1, ranging from mild (25%), moderate (31.2%) to marked (43.7%), while immunolabeling for anti-CK7 was detected only in one case of cholangiocarcinoma.(AU)

Os neoplasmas hepáticos primários são detectados em bovinos principalmente como achados incidentais em matadouros ou diagnosticados na necropsia, quando podem estar relacionados à causa da morte. A caracterização adequada dos tumores hepáticos primários é essencial para obter diagnósticos precisos, especialmente nas linhas de abate, com o propósito de reduzir condenações errôneas. Este trabalho teve o objetivo de determinar as características macroscópicas, histológicas e imuno-histoquímicas dos neoplasmas primários do fígado de bovinos abatidos em um matadouro-frigorífico no Sul do Brasil. Dezenove neoplasias hepáticas primárias foram identificadas. Macroscopicamente, os tumores hepáticos foram classificados de acordo com sua distribuição, como focais, multifocais ou difusos. Histologicamente, a forma e o arranjo das células e possíveis características malignas foram avaliados. Também foi realizada imuno-histoquímica (IHQ) para marcadores de epitélio biliar (anti-CK7) e hepatócitos (anti-Hep Par-1). O carcinoma hepatocelular (84,2%) foi o neoplasma hepático mais frequentemente detectado, seguido pelo colangiocarcinoma (15,8%). Esses tumores foram identificados apenas em vacas adultas. Os carcinomas hepatocelulares eram vistos como massas solitárias ou nódulos multifocais que na superfície de corte geralmente eram esverdeados. Os colangiocarcinomas foram observados como nódulos multifocais, ocasionalmente com aspecto umbilicado. Histologicamente, os padrões mais observados nos carcinomas hepatocelulares foram trabeculares e sólidos, enquanto nos colangiocarcinomas o arranjo sólido foi o mais frequente. Na IHQ, todos os carcinomas hepatocelulares foram marcados por anti-Hep Par-1, com marcação que variou de leve (25%), moderada (31,2%) a acentuada (43,7%); imunomarcação para anti-CK7 foi detectada em apenas um caso de colangiocarcinoma.(AU)
Descritores: Doenças dos Bovinos
Colangiocarcinoma/veterinária
Carcinoma Hepatocelular/veterinária
Neoplasias Hepáticas/patologia
Neoplasias Hepáticas/veterinária
Neoplasias Hepáticas/epidemiologia
-Matadouros
Limites: Animais
Bovinos
Responsável: BR68.1 - Biblioteca Virginie Buff D'Ápice


  2 / 445 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: lil-708905
Autor: Carreño Venegas, Andrea; Hurtado Guerra, Juan José; Navas Navas, María Cristina.
Título: Exposición a aflatoxina: un problema de salud pública / Exposition to aflatoxin: A public health problem
Fonte: Iatreia;27(1):42-52, ene.-mar. 2014. ilus, tab.
Idioma: es.
Resumo: La aflatoxina, una micotoxina producida por hongos contaminantes, es un potente tóxico hepático y un agente carcinógeno. La exposición a ella en la dieta es de particular importancia en ciertas regiones del Sureste de Asia y de África subsahariana, cuyas poblaciones presentan alta frecuencia de carcinoma hepatocelular y de la mutación en el codón 249 del gen p53; además, tienen alta prevalencia de la infección por el virus de la hepatitis B. Este factor de riesgo es muy importante si se tiene en cuenta que se ha demostrado sinergia entre la infección por dicho virus y la exposición a aflatoxina en la patogénesis del carcinoma hepatocelular. Pocos estudios han explorado la exposición a aflatoxinas en la dieta de la población latinoamericana y se desconoce el papel en ella de esta micotoxina como factor de riesgo para dicho carcinoma. En este artículo se presenta una revisión sobre diversos aspectos de las aflatoxinas, con énfasis en su relación con la infección por el virus de la hepatitis B y con el carcinoma hepatocelular.

Aflatoxin, a mycotoxin produced by pollutant molds, is a potent hepatotoxic and carcinogenic agent. Dietary exposition to it is of particular importance in certain regions of Southeast Asia and sub-Saharan Africa. Populations in these regions suffer from high incidence of hepatocellular carcinoma, and have high frequency of the mutation in the codon 249 of p53 gene; besides, prevalence of Hepatitis B virus (HBV) infection is high in those populations. Synergism between infection with HBV and the exposition to this mycotoxin in the pathogenesis of hepatocellular carcinoma has been demonstrated. Few studies have explored the exposition to aflatoxin in the diet of populations in Latin America, and the role in them of this mycotoxin as a risk factor for hepatocellular carcinoma is unknown. In this article different aspects of aflatoxin are reviewed with emphasis on its relationship with HBV infection and with such neoplasia.
Descritores: Aflatoxina B1/efeitos adversos
Aflatoxina B1/genética
Carcinoma Hepatocelular/etiologia
Hepatite B/etiologia
Limites: Humanos
Tipo de Publ: Revisão
Responsável: CO56.1 - Biblioteca


  3 / 445 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-1020731
Autor: San Martín M, Evelyn; Salgado F, Apolo; Véliz R, Ignacio; Villegas P, Cynthia; Vásquez F, Beatriz; Parra C, Vincka; Aros B, Jessica.
Título: Image-Guided BrachyAblation (IGBA) en hepatocarcinoma: descripción de la técnica y reporte del primer caso en Chile / Image-guided brachyablation for hepatocarcinoma: report of one case
Fonte: Rev. méd. Chile;147(6):808-812, jun. 2019. graf.
Idioma: es.
Resumo: Eighty percent of hepatocarcinomas are inoperable at the moment of diagnosis. Liver transplantation is the treatment of choice in these cases, but local therapies are another alternative. Among these, Image-Guided BrachyAblation is a safe choice. We report a 76-year-old male with a hepatocarcinoma, who was considered inoperable due to the high surgical risk of the patient. A local treatment with Image-Guided BrachyAblation was decided. A brachytherapy needle was placed in the tumor under computed tomography guidance and a 15 Gy single dose was delivered from an Iridium-192 source. The patient had no immediate complications and at one month of follow up he continued without incidents.
Descritores: Braquiterapia/métodos
Carcinoma Hepatocelular/radioterapia
Técnicas de Ablação/métodos
Radioterapia Guiada por Imagem/métodos
Neoplasias Hepáticas/radioterapia
-Doses de Radiação
Radioisótopos de Irídio
Tomografia Computadorizada por Raios X
Resultado do Tratamento
Carcinoma Hepatocelular/diagnóstico por imagem
Neoplasias Hepáticas/diagnóstico por imagem
Limites: Humanos
Masculino
Idoso
Tipo de Publ: Relatos de Casos
Responsável: CL1.1 - Biblioteca Central


  4 / 445 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-1038783
Autor: Cui, Chao; Li, Zhiyu; Wu, Dequan.
Título: The long non-coding RNA H19 induces hypoxia/reoxygenation injury by up-regulating autophagy in the hepatoma carcinoma cells
Fonte: Biol. Res;52:32, 2019. graf.
Idioma: en.
Resumo: BACKGROUND: Long non-coding RNA H19 (H19) plays an important role by regulating protein expression in different tissues and organs of the body. However, whether H19 induces hypoxia/reoxygenation (h/R) injury via increase of autophagy in the hepatoma carcinoma cells is unknown. RESULTS: H19 was expressed in the hepatoma carcinoma cells (Hep G2 and HCCLM3 cells) and its expression was most in 8 h/24R. The knockdown of H19 and 3-MA (an autophagy inhibitor) protected against h/R-induced apoptosis, cell damage, the expression of cleaved caspase-3 and cleaved caspase-9, the release of cytochrome c (Cyt c). The knockdown of H19 and 3-MA also decreased the autophagic vesicles (AVs) and the expression of Beclin-1 and the ration of LC3-II/LC3-I, and increased cell viability, the expression of Bcl-2 and P62 and the phosphorylation of PI3K, Akt and mTOR. In addition, chloroquine (CQ, an inhibitor of autophagy flux) markedly decreased formation of autophagy flux (the ration of LC3-II/LC3-I). The results of the knockdown of H19 group were similar to those of the 3-MA (or CQ) group. Rapamycin (a mTOR inhibitor, an autophagy activator) further down-regulated h/R-induced decrease of the phosphorylated PI3K, Akt and mTOR. The knockdown of H19 cancelled the effect of rapamycin. The overexpression of H19 further expanded h/R-induced increase of the ration of LC3-II/LC3-I and decrease of the phosphorylated PI3K, Akt and mTOR. CONCLUSIONS: Our results suggest that the long non-coding RNA H19 induces h/R injury by up-regulation of autophagy via activation of PI3K-Akt-mTOR pathway in the hepatoma carcinoma cells.
Descritores: Traumatismo por Reperfusão/metabolismo
Carcinoma Hepatocelular/metabolismo
RNA Longo não Codificante/metabolismo
Neoplasias Hepáticas/metabolismo
Hipóxia/metabolismo
-Oxigênio/metabolismo
Autofagia/efeitos dos fármacos
Regulação para Cima/fisiologia
Isquemia Encefálica/metabolismo
Apoptose/fisiologia
Carcinoma Hepatocelular/patologia
Neoplasias Hepáticas/patologia
Limites: Humanos
Responsável: CL1.1 - Biblioteca Central


  5 / 445 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Cotrim, Helma Pinchemel
Texto completo
Id: biblio-839211
Autor: Carvalho, Kellyane Santana Dias; Cotrim, Helma Pinchemel; Fonseca Junior, Luciano Espinheira; Moreira, Valéria; Sirqueira, Érika.
Título: Hepatocellular carcinoma in patients with B and C virus hepatitis without cirrhosis
Fonte: Braz. j. infect. dis;21(3):367-367, May-June 2017.
Idioma: en.
Descritores: Hepatite C/complicações
Carcinoma Hepatocelular/virologia
Hepatite B Crônica/complicações
Neoplasias Hepáticas/virologia
-Cirrose Hepática/virologia
Limites: Humanos
Tipo de Publ: Carta
Responsável: BR1.1 - BIREME


  6 / 445 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1131807
Autor: Miyama, Yu; Fujii, Takeshi; Murase, Kyoko; Takaya, Hisashi; Kondo, Fukuo.
Título: Hepatoid adenocarcinoma of the lung mimicking metastatic hepatocellular carcinoma
Fonte: Autops. Case Rep;10(2):e2020162, Apr.-June 2020. graf.
Idioma: en.
Resumo: Hepatoid adenocarcinoma of the lung is a rare subtype of lung cancer. We report a case of a metastatic hepatoid adenocarcinoma of the lung with aggressive behavior, including biopsy and autopsy findings. The pulmonary tumors showed features indistinguishable from hepatocellular carcinoma and were diffusely positive for Hepatocyte Paraffin 1.
Descritores: Adenocarcinoma
Carcinoma Pulmonar de Células não Pequenas
Carcinoma Hepatocelular
Neoplasias Pulmonares
-Autopsia
Evolução Fatal
Limites: Humanos
Masculino
Pessoa de Meia-Idade
Tipo de Publ: Relatos de Casos
Conferência Clínica
Responsável: BR26.7 - Serviço de Biblioteca e Documentação Científica


  7 / 445 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Alvares-da-Silva, Mario Reis
Texto completo
Id: biblio-1115980
Autor: Costa, Marisa Boff; Longo, Larisse; Santos, Deivid; Costa, Raquel Boff da; Dellavia, Gustavo Hirata; Arruda, Soraia; Michalczuk, Matheus Truccolo; Álvares-da-Silva, Mário Reis.
Título: Clinical and epidemiological profile of HCV genotype 3 patients in southern Brazil
Fonte: Clin. biomed. res;40(1):7-13, 2020.
Idioma: en.
Resumo: Introduction: Despite the emergence of new treatments for HCV genotype 3 (HCV G3), there is still a lack of data about this particular subgroup in Brazil. Our objective was to describe clinical and sociodemographic variables and treatment profile of HCV G3 Brazilian patients. Methods: This was a descriptive, retrospective study, performed in a specialized center for HCV treatment in the South Region of Brazil. Medical records of patients diagnosed with HCV G3 were reviewed to collect clinical, sociodemographic, and treatment information. Results: Participants included total of 564 patients, with a mean age of 59.3 years (SD = 10.5). Cirrhosis was present in 54.4% of patients. The most common coexisting conditions were systemic arterial hypertension (36.6%) and diabetes mellitus (30%). Regarding treatment, 25.2% of the patients were treatment-naïve and 74.8% were currently under treatment (11.6%) or had received a previous treatment (87%). The most frequent ongoing treatment was sofosbuvir + daclatasvir (± ribavirin) (87.8%). Of the 388 patients who had at least one previous treatment, 67% achieved sustained virologic response in the last treatment. Caucasian / white, non-obese, transplanted patients, those with longer time since diagnosis and with cirrhosis were more likely to receive treatment, according to multivariate analysis. Patients with hepatocellular carcinoma were 64.1% less likely to be on treatment during the study period than those without this condition; patients with chronic kidney disease were 2.91-fold more likely to have an interruption of treatment than those without this condition. Conclusion: This study describes a large sample of Brazilian patients with HCV G3. Treatment patterns were mainly influenced by the presence of HCV complications and comorbidities.(AU)
Descritores: Hepatite C/virologia
Hepacivirus/genética
Genótipo
-Antivirais/uso terapêutico
Ribavirina/uso terapêutico
Estudos Retrospectivos
Interferons/uso terapêutico
Hepatite C/tratamento farmacológico
Hepatite C/epidemiologia
Carcinoma Hepatocelular/tratamento farmacológico
Suspensão de Tratamento
Sofosbuvir/uso terapêutico
Cirrose Hepática/tratamento farmacológico
Limites: Humanos
Masculino
Feminino
Adolescente
Adulto
Pessoa de Meia-Idade
Idoso
Adulto Jovem
Responsável: BR18.1 - Biblioteca FAMED/HCPA


  8 / 445 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-888892
Autor: Cunha-Silva, Marlone; Marinho, Fábio R T; Oliveira, Paulo F; Lopes, Tirzah M; Sevá-Pereira, Tiago; Lorena, Sonia L S; Almeida, Jazon R S.
Título: Retrospective analysis of hepatitis B virus chronic infection in 247 patients: clinical stages, response to treatment and poor prognostic factors
Fonte: Braz. j. infect. dis;21(4):441-447, July-Aug. 2017. tab, graf.
Idioma: en.
Resumo: Abstract Background: Chronic hepatitis B is a major cause of cirrhosis, and the natural history of the disease has several clinical stages that should be thoroughly understood for the implementation of proper treatment. Nonetheless, curing the disease with antiviral treatment remains a challenge. Aims: To describe the clinical course, response to treatment, and poor prognostic factors in 247 hepatitis B virus chronic infection patients treated in a tertiary hospital in Brazil. Methods: This was a retrospective and observational study, by analyzing the medical records of HBV infected patients between January 2000 and January 2015. Results: Most patients were male (67.2%) and 74.1% were HBeAg negative. Approximately 41% had cirrhosis and 8.5% were hepatitis C virus coinfected. The viral load was negative after two years on lamivudine, entecavir and tenofovir in 86%, 90.6%, and 92.9% of the patients, respectively. The five-year resistance rates for lamivudine, adefovir, entecavir, and tenofovir were 57.5%, 51.8%, 1.9%, and 0%, respectively. The overall seroconversion rates were 31.2% for HBeAg and 9.4% for HBsAg. Hepatocellular carcinoma was diagnosed in 9.7% of patients, liver transplantation was performed in 9.7%, and overall mortality was 10.5%. Elevations of serum alanine aminotransferase (p = 0.0059) and viral load (p < 0.0001) were associated with progression to liver cirrhosis. High viral load was associated with progression to hepatocellular carcinoma (p < 0.0001). Significant risk factors associated with death were elevated alanine aminotransferase (p = 0.0039), liver cirrhosis (p < 0.0001), high viral load (p = 0.007), and hepatocellular carcinoma (p = 0.0008). HBeAg positive status was not associated with worse outcomes, and treatment may have been largely responsible. Conclusions: Elevations of viral load and serum alanine aminotransferase may select patients with worse prognosis, especially progression to cirrhosis and hepatocellular carcinoma, which were strongly association with death.
Descritores: Antivirais/uso terapêutico
Vírus da Hepatite B/imunologia
Carcinoma Hepatocelular/virologia
Hepatite B Crônica/tratamento farmacológico
Cirrose Hepática/virologia
Neoplasias Hepáticas/virologia
-Prognóstico
Estudos Retrospectivos
Fatores de Risco
Carcinoma Hepatocelular/mortalidade
Progressão da Doença
Carga Viral
Hepatite B Crônica/complicações
Hepatite B Crônica/mortalidade
Cirrose Hepática/mortalidade
Neoplasias Hepáticas/mortalidade
Limites: Humanos
Masculino
Feminino
Adolescente
Adulto
Pessoa de Meia-Idade
Idoso
Idoso de 80 Anos ou mais
Adulto Jovem
Tipo de Publ: Estudo Observacional
Responsável: BR1.1 - BIREME


  9 / 445 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-1019499
Autor: Wang, Xiaomin; Peng, Peike; Pan, Zhiqiang; Fang, Zhaoqin; Lu, Wenli; Liu, Xiaomei.
Título: Psoralen inhibits malignant proliferation and induces apoptosis through triggering endoplasmic reticulum stress in human SMMC7721 hepatoma cells
Fonte: Biol. Res;52:34, 2019. tab, graf.
Idioma: en.
Projeto: National Natural Science Foundation of China.
Resumo: BACKGROUND: Psoralen is a coumarin-like and coumarin-related benzofuran glycoside, which is a commonly used traditional Chinese medicine to treat patients with kidney and spleen-yang deficiency symptom. Psoralen has been reported to show estrogen-like activity, antioxidant activity, osteoblastic proliferation accelerating activity, antitumor effects and antibacterial activity. However, the antitumor mechanism of psoralen is not fully understood. This study aimed to investigate the therapeutic efficacy of psoralen in human hepatoma cell line SMMC7721 and the mechanism of antitumor effects. RESULTS: Psoralen inhibited proliferation of SMMC7721 in a dose- and time-dependent manner, and promoted apoptosis. Further, psoralen activated the ER stress signal pathway, including the expansion of endoplasmic reticulum, increasing the mRNA levels of GRP78, DDIT3, ATF4, XBP1, GADD34 and the protein levels of GDF15, GRP78, IRE1α, XBP-1s in a time-dependent manner. Psoralen induces cell cycle arrest at G1 phase by enhancing CyclinD1 and reducing CyclinE1 expression. Moreover, TUDC couldn't inhibit the psoralen-induced ER stress in SMMC7721 cells. CONCLUSIONS: Psoralen can inhibit the proliferation of SMMC7721 cells and induce ER stress response to induce cell apoptosis, suggesting that psoralen may represent a novel therapeutic option for the prevention and treatment hepatocellular carcinoma.
Descritores: Carcinoma Hepatocelular/tratamento farmacológico
Proliferação de Células/efeitos dos fármacos
Estresse do Retículo Endoplasmático/efeitos dos fármacos
Ficusina/farmacologia
Neoplasias Hepáticas/tratamento farmacológico
Antineoplásicos Fitogênicos/farmacologia
-Transdução de Sinais/efeitos dos fármacos
Proteínas Serina-Treonina Quinases/farmacologia
Apoptose/efeitos dos fármacos
Carcinoma Hepatocelular/patologia
Linhagem Celular Tumoral
Ficusina/uso terapêutico
Ficusina/química
Neoplasias Hepáticas/patologia
Limites: Humanos
Responsável: CL1.1 - Biblioteca Central


  10 / 445 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-1019501
Autor: Wang, Wenting; Zhu, Mingyue; Xu, Zhixin; Li, Wei; Dong, Xu; Chen, Yi; Lin, Bo; Li, Mengsen.
Título: Ropivacaine promotes apoptosis of hepatocellular carcinoma cells through damaging mitochondria and activating caspase-3 activity
Fonte: Biol. Res;52:36, 2019. graf.
Idioma: en.
Projeto: National Natural Science Foundation of China; . Natural Science Foundation of Hainan Province; . Undergraduate Student Innovate Project of Hainan Medical College.
Resumo: BACKGROUND: Recent evidences indicated that some local anaesthetic agents played a role in inhibiting the proliferation of cancer cells; Whether ropivacaine is able to promote apoptosis of hepatocellular carcinoma (HCC) cells is still unclear. The aim of this study was to investigate the effect of ropivacaine on the apoptosis of HCC cells. METHODS: In the present study, we treated the HCC cell lines, Bel7402 and HLE with ropivacaine. MTT, DAPI stain, trypan blue exclusion dye assay, flow cytometry, electron microscopy, computational simulation, laser confocal microscope, Western blotting, and enzyme activity analysis of caspase-3 were applied to detect the growth and apoptosis of HCC cells and to explore the role mechanism of ropivacaine. RESULTS: Ropivacaine was able to inhibit proliferation and promote apoptosis of HCC cells in a dose- and time-dependent manner. Ropivacaine also has a trait to inhibit the migration of HCC cells; ropivacaine damaged the mitochondria of HCC cells. The results also indicated that ropivacaine was able to interact with caspase-3, promote cytoplasmic caspase-3 migration into the nucleus, stimulate cleavage of caspase-3 and PARP-1, caspase-9 proteins, inhibit the expression of Bcl-2, promote expression of Apaf-1 and mitochondria release cytochrome C, and activate the activity of caspase-3. CONCLUSIONS: Ropivacaine has a novel role in promoting apoptosis of HCC cells; The role mechanism of ropivacaine maybe involve in damaging the function of mitochondria and activating the caspase-3 signalling pathway in HCC cells. Our findings provide novel insights into the local anaesthetic agents in the therapy of HCC patients.
Descritores: Apoptose/efeitos dos fármacos
Carcinoma Hepatocelular/patologia
Caspase 3/metabolismo
Ropivacaina/farmacologia
Anestésicos Locais/farmacologia
Neoplasias Hepáticas/patologia
-Transdução de Sinais/efeitos dos fármacos
Apoptose/fisiologia
Carcinoma Hepatocelular/metabolismo
Microscopia Confocal
Linhagem Celular Tumoral
Proliferação de Células/efeitos dos fármacos
Citometria de Fluxo
Neoplasias Hepáticas/metabolismo
Microscopia de Fluorescência
Mitocôndrias/efeitos dos fármacos
Limites: Humanos
Responsável: CL1.1 - Biblioteca Central



página 1 de 45 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde